


DAFTAR PUSTAKA

- Alqahtani, J.S., Oyelade, T., Aldhahir, A.M., Alghamdi, S.M., Almeahmadi, M., Quaderi, JS., Mandal, S., Hurst, J. (2020). 'Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis', *PLOS ONE*. Edited by G. C. Bhatt, 15(5), p. e0233147. doi: 10.1371/journal.pone.0233147.
- Arteaga-Livias, K., Pinzas-Acosta, K., Perez-Abad, L., Panduro-Correa, V., Rabaan, A.A., Pecho-Silva, S., Dámaso-Mata, B. (2022). 'A multidrug-resistant *Klebsiella pneumoniae* outbreak in a Peruvian hospital: Another threat from the COVID-19 pandemic', *Infection Control & Hospital Epidemiology*, 43(2), pp. 267–268. doi: 10.1017/ice.2020.1401.
- Başı, N.B., Metin, S., Sevinç, S.A., Salkaya, A., Peker, N., Çınar, A.S., Altuntaş, Y., Özdemir, H.M. (2022). 'The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized Intensive Care Unit in Covid-19 Pandemic', *Acta Biomedica*, 93(3), pp. 1–7. doi: 10.23750/abm.v93i3.11880.
- Bazaid, A.S., Barnawi, H., Qanash, H., Alsaif, G., Aldarhami, A., Gattan, H., Alharbi, B., Alrashidi, A., Al-Soud, W.A., Moussa, S., Alfouzan, F. (2022). 'Bacterial Coinfection and Antibiotic Resistance Profiles among Hospitalised COVID-19 Patients', *Microorganisms*, 10(3), p. 495. doi: 10.3390/microorganisms10030495.
- Bertram, S., Glowacka, I., Müller, M.A., Lavender, H., Gnirss, K., Nehlmeier, I., Niemeyer, D., He, Y., Simmons, G., Drosten, C., Soilleux, E.J., Jahn, O., Steffen, I., Pöhlmann, S. (2011). 'Cleavage and Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by Human Airway Trypsin-Like Protease', *Journal of Virology*, 85(24), pp. 13363–13372. doi: 10.1128/jvi.05300-11.
- Bengoechea, J.A., & Bamford, C.G. (2020). SARS-CoV-2, bacterial co-infections, and AMR: the deadly trio in COVID-19?. *EMBO Molecular Medicine* 12. <https://doi.org/10.15252/emmm.202012560>
- Bernardo, A.M., Maria, F.G., Nereyda, A.D., Karla, M.T., Carla, M.R., Sandra, R.L., Ivonne, V.Z., Norma, I.L., Areli, M.G., Jose, S.O., Edgar, O.B., Eric, O.H., Arturo, G.F., Miriam, B., & Alfredo, P. (2021). Antimicrobial resistance patterns and antibiotic use during hospital

- Borges, I., Carneiro, R., Bergo, R., Martins, L., Colosimo, E., Oliveira, C., Saturnino, S., Andrade, M.V., Ravetti, C., Nobre, V. (2020). 'Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers', *Critical Care*, 24(1), p. 281. doi: 10.1186/s13054-020-02946-y.
- Bornstein, S.R., Rubino, F., Khunti, F., Mingrone, G., Hopkins, D., Birkenfeld, A.L., Boehm, B., Amiel, S., Holt, R.I., Skyler, J.S., DeVries, J.H., Renard, E., Eckel, R.H., Zimmet, P., Alberti, K.G., Vidal, J., Geloneze, B., Chan, J.C., Ji, L., Ludwig, B. (2020). 'Practical recommendations for the management of diabetes in patients with COVID-19', *The Lancet Diabetes & Endocrinology*, 8(6), pp. 546–550. doi: 10.1016/S2213-8587(20)30152-2.
- Bouadma, L., Luyt, C.E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., Bernard, M., Pasquet, B., Régnier, B., Brun-Buisson, C., Chastre, J., Wolff, M. (2010). 'Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial', *The Lancet*, 375(9713), pp. 463–474. doi: 10.1016/S0140-6736(09)61879-1.
- Channappanavar, R., & Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, *Seminars in Immunopathology*, 39(5), pp. 529–539. doi: 10.1007/s00281-017-0629-x.
- Channappanavar, R., Fett, C., Mack, M., Eyck, P.T., Meyerholz, D.K., Perlman, S. (2018). 'Sex-based differences in susceptibility to SARS-CoV infection', 198(10), pp. 319–335. doi: 10.4049/jimmunol.1601896.Sex-based.
- Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis, *Journal of Medical Virology*, 92(4), pp. 418–423. doi: 10.1002/jmv.25681.
- Cheng, K., He, M., Shu, Q., Wu, M., Chen, C., & Xue, Y. (2020). Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary hospital. *Risk Management and Healthcare Policy* 13. 2593.
- Clinical management of COVID-19* (2020). Available at: <https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19> (Accessed: 1 Maret 2022).
- Contou, D., Claudinon, A., Pajot, O., Micaelo, M., Flandre, P.L., Dubert, M., Cally, R., Logre, E., Fraisse, M., Mentec, H., & Plantefeve, G. (2020). Bacterial and viral co-infections in patients

- Coronavirus Disease (COVID-19) Situation Reports* (2020). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (Accessed: 1 Maret 2022).
- Costa, R.L., Lamas, C.C., Simvoulidis, L.F., Espanha, C.A., Moreira, L.P., Bonancim, R.A., Weber, J.V., Ramos, M.R., Silva, E.C., Oliveira, L.P. (2022). Secondary infections in a cohort of patients with COVID-19 admitted to an intensive care unit : impact of gram-negative bacterial resistance. *Revista do Instituto de Medicina Tropical de Sao Paulo* 64. <https://doi.org/10.1590/s1678-9946202264006>
- De Jong, E., Oers, J.A., Beishuizen, A., Vos, P., Vermeijden, W.J., Haas, L.E., Loeff, B.G., Dormans, T., Melsen, G.C., Kluiters, Y.C., Kemperman, H., Elsen, M.J., Schouten, J.A., Streefkerk, J.O., Krabbe, H.G., Kieft, H., Kluge, G.H., Dam, V.C., Elt, J., Bormans, L., Otten, M.B., Reidinga, A.C., Endeman, H., Twisk, J.W., Garde, M.W., Smet, A.M., Kesecioglu, J., Girbes, A.R., Nijsten, M.W., Lange, D.W. (2016). 'Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial', *The Lancet Infectious Diseases*, 16(7), pp. 819–827. doi: 10.1016/S1473-3099(16)00053-0.
- Do Nascimento, I.J., Cacic, N., Abdulazeem, H.M., Groote, T.C., Jayarajah, U., Weerasekara, I., Esfahani, M.A., Civile, V.T., Marusic, A., Jeroncic, A., Junior, N.C., Pericic, T.P., Zakarija-Grkovic, I., Guimarães, S.M., Bragazzi, N.L., Bjorklund, M., Sofi-Mahmudi, A., Altujjar, M., Tian, M., Arcani, D.M., O'Mathúna, D.P., Marcolino, M.S. (2020). 'Novel coronavirus infection (Covid-19) in humans: A scoping review and meta-analysis', *Journal of Clinical Medicine*, 9(4). doi: 10.3390/jcm9040941.
- Dharaniyadewi, D., Chen, L.K., & Suwanto, S. (2015). Peran *procalcitonin* sebagai penanda inflamasi sistemik pada sepsis. *Jurnal Penyakit Dalam Indonesia Vol.2*, 116-123.
- Fu, Y., Yang, Q., Xu, M., Kong, H. Chen, H., Fu, Y., Yao, Y., Zhou, H., & Zhou J. (2020). Secondary bacterial infections in critical ill patients with coronavirus disease 2019. *Open forum infectious disease* 7. <https://doi.org/10.1093/ofid/ofaa220>
- Garcia, C.V., Sanjuan, G., García, E.M., Alcalde, P.P., Pouton, N.G., Chumbita, M., Pittol, M.F., Pitart, C., Inciarte, A., Bodro, M., Morata, L., Ambrosini, J., Grafia, I., Meira, F., Macaya, I., Cardozo, C., Casals, C., Tellez, A., Castro, P., Marco, F., Garcia, F., Mensa, J., Martinez, J.A., & Soriano, A. (2021). Incidence of co-infections and superinfections in hospitalized

- Goyal, P., Choi, J.J., Pinheiro, L.C., Schenck, E.J., Chen, R., Jabri, A., Satlin, M.J., Campion, T.R., Nahid, M., Ringel, J.B., Hoffman, K.L., Alshak, M.N., Li, H.A., Wehmeyer, G.T., Rajan, M., Reshetnyak, E., Hupert, N., Horn, E.M., Martinez, F.J., Gulick, R.M., Safford, M.M. (2020). 'Clinical Characteristics of Covid-19 in New York City', *New England Journal of Medicine*, 382(24), pp. 2372–2374. doi: 10.1056/NEJMc2010419.
- Grasselli, G., Cattaneo, E., Florio, G. (2021). Secondary infections in critically ill patients with COVID-19. *Annual Update in Intensive Care and Emergency Medicine 2021*. <https://doi.org/10.1186/s13054-021-03672-9>
- Grasselli, G., Tonetti, T., Protti, A., Langer, T., Girardis, M., Bellani, G., Laffey, J., Carrafiello, G., Carsana, L., Rizzuto, C., Zanella, A., Scaravilli, V., Pizzilli, G., Grieco, D.L., Meglio, L.D., Pascale, G.D., Lanza, E., Monteduro, F., Zompatori, M., Filippini, C., Locatelli, F., Cecconi, M., Fumagalli, R., Nava, S., Vincent, J.L., Antonelli, M., Slutsky, A.S., Pesenti, A., & Ranieri, V.M. (2020). Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study, *The Lancet Respiratory Medicine*, p. S2213260020303702. doi: 10.1016/S2213-2600(20)30370-2.
- Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., Iotti, G., Latronico, N., Lorini, L., Merler, S., Natalini, G., Piatti, A., Ranieri, M.V., Scandroglio, A.M., Storti, E., Cecconi, M., Pesenti, A. (2020). 'Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy', *JAMA*, 323(16), p. 1574. doi: 10.1001/jama.2020.5394.
- Guan, W.J., Liang, W.H., Zhao, Y., Liang, H.R., Chen, Z.S., Li, Y.M., Liu, X.Q., Chen, R.C., Tang, C.L., Wang, T., Ou, C.Q., Li, L., Chen, P.Y., Sang, L., Wang, W., Li, J.F., Li, C.C., Ou, L.M., Cheng, B., Xiong, S. (2020). 'Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis', *European Respiratory Journal*, 55(5), p. 2000547. doi: 10.1183/13993003.00547-2020.
- Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A.L., Mudatsir, M. (2020). Coronavirus disease 2019 (COVID-19): A literature review, *Journal of Infection and Public Health*, 13(5), pp. 667–673. doi: 10.1016/j.jiph.2020.03.019.

- 
- Hubungan Antara Kesesuaian Terapi Antibiotik Empiris Dan Kadar Procalcitonin Pada Pasien Covid-19 Yang Disertai Dengan Infeksi Sekunder Bakteri Paru Di ICU RSUP Dr Sardjito
Febrian Naufaldi, dr. Calcarifia Fitrianti R.W., Sp.An, KIC., dr. Akhmad Yuh Jufah, Sp.An, M.Sc., KIC., Universitas Gadjah Mada, 2023. Diunduh dari <http://etd.repository.ugm.ac.id/>
- Huang, C., Wang, Y., Li, X., Ren, Z., Yang, Z., Xu, J., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *The Lancet*, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
- Iaccarino, G., Grassi, G., Borghi, C., Carugo, S., Fallo, F., Ferri, C., Giannattasio, C., Grassi, D., Letizia, C., Mancusi, C., Minuz, P., Perlini, S., Pucci, G., Rizzoni, D., Salvetti, M., Sarzani, R., Sechi, L., Veglio, F., Volpe, M., Muiesan, M.L. (2020). ‘Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the italian society of hypertension’, *PLoS ONE*, 15(10 October), pp. 1–12. doi: 10.1371/journal.pone.0237297.
- Jeong, S., Lee, N., Park, Y., Kim, J., Jeon, K., Park, M.J., & Song, W. (2022). Prevalence and clinical impact of coinfection in patients with coronavirus disease 2019 in Korea. *Viruses* 14, 446. <https://doi.org/10/3390/v14020446>
- Katzung, B.G., Masters, S.B., & Trevor, A.J. (2014). *Farmakologi Dasar dan Klinik*. Edisi 12. Jakarta: EGC
- Kooistra, E.J., Berkel, M., Kempen, N.V., Latum, C.R., Bruse, N., Frenzel, T., Berg, M.J., Schouten, J.A., Kox, M., Pickkers, P. (2021). ‘Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients’, *Critical Care*, 25(1), p. 281. doi: 10.1186/s13054-021-03717-z.
- Kumar, A., Arora, A., Sharma, P., Anikhindi, S.A., Bansal, N., Singla, V., Khare, S., Srivastava, A. (2020). ‘Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis’, *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14(4), pp. 535–545. doi: 10.1016/j.dsx.2020.04.044.
- Kyriazopoulou, E. and Giamarellos-Bourboulis, E. J. (2022) ‘Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill’, *Antibiotics*, 11(3), pp. 1–16. doi: 10.3390/antibiotics11030367.
- Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases* (2020). Available at: <https://www.who.int/publications-detail-redirect/10665-331501> (Accessed: 1 Maret 2022).
- Langford, B.J., So, M., Raybardhan, S., Leung, V., Westwood, D., MacFadden, D.R., Soucy, J.R., Daneman, N. (2020). ‘Bacterial co-infection and secondary infection in patients with

- Lippi, G. and Sanchis-Gomar, F. (2017) ‘Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities’, *World Journal of Gastroenterology*, 23(47), pp. 8283–8290. doi: 10.3748/wjg.v23.i47.8283.
- Manohar, P., Loh, B., Nachimuthu, R., Hua, X., Welburn, S.C., & Leptihn, S. (2020). Secondary bacterial infections in patients with viral pneumonia. *Frontiers in Medicine* 7. <https://doi.org/10.3389/fmed.2020.00420>
- Maurizi, G., Guardia, L.D., Maurizi, A., Poloni, A. (2018). ‘Adipocytes properties and crosstalk with immune system in obesity- related inflammation’, *Journal of Cellular Physiology*, 233(1), pp. 88–97. doi: 10.1002/jcp.25855.
- Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J. (2020). ‘COVID-19: consider cytokine storm syndromes and immunosuppression’, *The Lancet*, 395(10229), pp. 1033–1034. doi: 10.1016/S0140-6736(20)30628-0.
- Meisner, M. (2014) ‘Update on Procalcitonin Measurements’, *Annals of Laboratory Medicine*, 34(4), pp. 263–273. doi: 10.3343/alm.2014.34.4.263.
- Montrucchio, G., Corcione, S., Sales, G., Curtoni, A., De Rosa, F.G., Brazzi, L. (2020). ‘Carbapenem-resistant *Klebsiella pneumoniae* in ICU-admitted COVID-19 patients: Keep an eye on the ball’, *Journal of Global Antimicrobial Resistance*, 23, pp. 398–400. doi: 10.1016/j.jgar.2020.11.004.
- Paudel, R., Dogra, P., Montgomery-Yates, A.A., Yataco, A.C. (2020). ‘Procalcitonin: A promising tool or just another overhyped test?’, *International Journal of Medical Sciences*, 17(3), pp. 332–337. doi: 10.7150/ijms.39367.
- Piroth, L., Cottenet, J., Mariet, S., Bonniaud, P., Blot, M., Tubert-Bitter, P., Quantin, C. (2021). ‘Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study’, *The Lancet Respiratory Medicine*, 9(3), pp. 251–259. doi: 10.1016/S2213-2600(20)30527-0.
- Preas, H.L., Nylen, E.S., Snider, R.H., Becker, K.L., White, J.C., Agosti, J.M., Suffredini, A.F. (2001). ‘Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia’, *Journal of Infectious Diseases*, 184(3), pp. 373–376. doi: 10.1086/322031.
- Rhee, C. (2017). Using Procalcitonin to Guide Antibiotic Therapy. *Open forum Infectious Disease*, 4(1), 294.

- Rawson, T.M., Moore, L.S., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., Holmes, A. (2020). 'Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing', *Clinical Infectious Diseases*. doi: 10.1093/cid/ciaa530.
- Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R.A., Wootton, D.G., Sigfrid, L., Harrison, E.M., Docherty, A.B., Silva, T.I., Egan, C., Pius, R., Hardwick, H.E., Merson, L., Girvan, M., Dunning, J., Tam, J.S., Openshaw, P.J.M., Baillie, J.K., Semple, M.G., & Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. *The Lancet Microbe*.
- Santis, V.D., Corona, A., Vitale, D. 2021. Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study. *Infection*, 1-10
- Sattar, N., McInnes, I. B. and McMurray, J. J. V. (2020) 'Obesity Is a Risk Factor for Severe COVID-19 Infection', *Circulation*, 142(1), pp. 4–6. doi: 10.1161/CIRCULATIONAHA.120.047659.
- Shafran, N., Shafran, I., Ben-Zvi, H., Sofer, S., Sheena, L., Krause, I., Shlomai, A., Goldberg, E., Sklan, E.H. (2021). 'Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients', *Scientific Reports*, 11(1), p. 12703. doi: 10.1038/s41598-021-92220-0.
- Sieswerda, E., Boer, M.G.J., Bonten, M.M.J., Boersma, W.G., Jonkers, R.E., Aleva, R.M., Kullberg, B.J., Schouten, J.A., Garde, E.M., Verheji, T.J., Eerden, M.M., Prins, J.M., & Wiersinga, W.J. (2020). Recommendations for antibacterial therapy in adults with COVID-19 - An evidence based guideline. *Clinical Microbiology and Infection*, 27(2021), 61-66
- Silva, A.R.O., Salgado, R.O., Lopes, L.P., Castanheira, D., Emmerick, I.C.M., Lima, E.C. (2021). 'Increased Use of Antibiotics in the Intensive Care Unit During Coronavirus Disease (COVID-19) Pandemic in a Brazilian Hospital', *Frontiers in Pharmacology*, 12. doi: 10.3389/fphar.2021.778386.
- Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Noulette, J., Duhamel, A., Labreuche, J., Mathieu, D., Pattou, F., Jourdain, M. (2020). 'High Prevalence of Obesity in Severe Acute

- Sreenath, K., Batra, P., Vinayaraj, E.V., Bhatia, R., Saikiran, K., Singh, V., Singh, S., Verma, N., Singh, U.B., Mohan, A., Bhatnagar, S., Trikha, A., Guleria, R., Chaudhry, R. (2021). ‘Coinfections with Other Respiratory Pathogens among Patients with COVID-19’, *Microbiology Spectrum*. Edited by T. Jhaveri, 9(1). doi: 10.1128/Spectrum.00163-21.
- Ticinesi, A., Nouvenne, A., Prati, B., Guida, L., Parise, A., Cerundolo, N., Bonaguri, C., Aloe, R., Guerra, A., & Meschi, T. (2021). The clinical significance of procalcitonin elevation in patients over 75 years old admitted for COVID-19 Pneumonia. *Hindawi Mediators of Inflammation* 2021. <https://doi.org/10.1155/2021/5593806>
- Vijay, S., Bansal, N., Rao, B.K., Veeraraghavan, B., Rodrigues, C., Wattal, C., Goyal, J.P., Tadepalli, K., Mathur, P., Venkateswaran, R., Venkatasubramanian, R., Khadangan, S., Bhattacharya, S., Mukherjee, S., Baveja, S., Sistla, S., Panda, S., & Walia, K. (2021). Secondary infections in hospitalized COVID-19 patients: Indian experience. *Infect drug resist* 14, 1893.
- Wang, H., Paulson, K.R., Pease, S.A., Watson, S., Comfort, H., Zheng, P., Aravkin, A.Y., Bisignano, C., Barber, R.M., Alam, T., Fuller, J.E., May, E.A., Jones, D.P. (2022). ‘Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21’, *The Lancet*, 399(10334), pp. 1513–1536. doi: 10.1016/S0140-6736(21)02796-3.
- Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., Zhou, Y. (2020). ‘Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis’, *International Journal of Infectious Diseases*, 94, pp. 91–95. doi: 10.1016/j.ijid.2020.03.017.
- Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., Shang, Y. (2020). ‘Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study’, *The Lancet Respiratory Medicine*, 8(5), pp. 475–481. doi: 10.1016/S2213-2600(20)30079-5.
- Zhang, H., Zhang, Y., Wu, J., Li, Y., Zhou, X., Li, X., Chen, H., Guo, M., Chen, S., Sun, F., Mao, R., Qiu, C., Zhu, Z., Ai, J., & Zhang, W. (2020). Risks and features of secondary infections in severe and critical ill COVID-19 patients. *Emerging microbes & infections*, 9(1), 1958–1964.

- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., Cao, B. (2020). 'Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study', *The Lancet*, 395(10229), pp. 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
- Zhu, X., Ge, Y., Wu, T., Zhao, K., Chen, Y., Wu, B., Zhu, F., Zhu, B., Cui, L. (2020). 'Co-infection with respiratory pathogens among COVID-2019 cases', *Virus Research*, 285, p. 198005. doi: 10.1016/j.virusres.2020.198005.